The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Dennis Wolf Christoph Bode |
| Publication date | June 23, 2011 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |